Benjamin Lightburn - Filament Health CEO CoFounder

FLHLF Stock  USD 0.03  0.01  14.29%   

Insider

Benjamin Lightburn is CEO CoFounder of Filament Health Corp
Age 37
Webhttps://filament.health

Filament Health Management Efficiency

The company has return on total asset (ROA) of (0.2133) % which means that it has lost $0.2133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4004) %, meaning that it generated substantial loss on money invested by shareholders. Filament Health's management efficiency ratios could be used to measure how well Filament Health manages its routine affairs as well as how well it operates its assets and liabilities.
Filament Health Corp has accumulated 868.91 K in total debt with debt to equity ratio (D/E) of 0.06, which may suggest the company is not taking enough advantage from borrowing. Filament Health Corp has a current ratio of 4.02, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Filament Health until it has trouble settling it off, either with new capital or with free cash flow. So, Filament Health's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Filament Health Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Filament to invest in growth at high rates of return. When we think about Filament Health's use of debt, we should always consider it together with cash and equity.
Filament Health Corp. operates as a natural psychedelic drug discovery and extraction technology company. It propagates psychedelic plants conducts genetic research performs extraction procedures runs in-house trials and distributes IP and drug candidates to drug developers, researchers, and other licensed parties. Filament Health is traded on OTC Exchange in the United States. Filament Health Corp [FLHLF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Filament Health Corp Leadership Team

Elected by the shareholders, the Filament Health's board of directors comprises two types of representatives: Filament Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Filament. The board's role is to monitor Filament Health's management team and ensure that shareholders' interests are well served. Filament Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Filament Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jon Conlin, Corp Director
Jeff Fellows, Head Regulatory
Benjamin Lightburn, CEO CoFounder
Tom Kineshanko, CoFounder
Warren Duncan, Chief Officer
Lisa Ranken, Chief Officer
Anna Cordon, Director Communications
Ryan Moss, Chief Officer

Filament Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Filament Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Filament OTC Stock

Filament Health financial ratios help investors to determine whether Filament OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Filament with respect to the benefits of owning Filament Health security.